Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Cefuroxime is the active ingredient of these drugs:
Turkey
Hong Kong South Africa
Ecuador
Ireland
Austria Finland France Hong Kong Netherlands
South Africa
Turkey
Hong Kong
Cyprus Estonia Hong Kong Lithuania Romania
Ecuador
Singapore
South Africa
Ecuador
Poland
Poland
Turkey
South Africa
Romania
Turkey
Hong Kong
Poland
Turkey
Ireland
Singapore
Turkey
South Africa
South Africa
Ecuador
Cyprus Germany Turkey
Ecuador
Ecuador
Turkey
Ecuador
Hong Kong
Ecuador
Hong Kong
Ecuador
Ecuador
Ecuador Poland South Africa
South Africa
Hong Kong
South Africa
Austria
Italy
Hong Kong
Estonia Germany
Turkey
Hong Kong
Ecuador
Estonia Hong Kong Poland
Ecuador
Turkey
France
Turkey
Cyprus
Ecuador
Italy
Brazil
South Africa
Brazil
Turkey
Turkey
Turkey
Italy
Ecuador
Turkey
Spain
Lithuania
Lithuania
Turkey
Turkey
Turkey
Turkey
Hong Kong
Singapore
Poland
Poland
Italy
Turkey
Tunisia
Austria Estonia Lithuania Netherlands Poland
Ecuador
Ecuador Estonia Hong Kong Lithuania Poland
Hong Kong
Ecuador Poland
Spain
Turkey
South Africa
South Africa
Hong Kong
Brazil
Tunisia
Cyprus New Zealand
Brazil Cyprus Estonia Finland Hong Kong
Australia Austria Brazil Cyprus Ecuador
Tunisia
South Africa
Poland